Zhenoluten
Hormonal / FertilityAlso known as: Ovary Bioregulator, Khavinson Ovary Peptide, Female Reproductive Bioregulator
Mechanism
Zhenoluten is a peptide bioregulator specifically targeting ovarian tissue and female reproductive function. As women age, ovarian reserve declines and hormonal production shifts — leading to irregular cycles, reduced fertility, and eventually menopause. Zhenoluten aims to support ovarian cell function by restoring healthy gene expression patterns in granulosa cells and theca cells, potentially improving estrogen and progesterone production. It is used by women seeking to support reproductive longevity and ease the menopausal transition.
Technical detail
Zhenoluten is a short-chain peptide bioregulator from the Khavinson series targeting ovarian granulosa cells, theca cells, and ovarian stromal tissue. Proposed mechanism: nuclear DNA interaction to modulate expression of steroidogenic enzymes (CYP19A1/aromatase for estrogen synthesis, 3β-HSD for progesterone), gonadotropin receptors (FSHR, LHCGR), and anti-Müllerian hormone (AMH) in granulosa cells. May support follicular development by modulating growth factor expression (GDF-9, BMP-15) critical for oocyte-granulosa cell communication. Potentially influences ovarian aging by modulating oxidative stress pathways and telomere maintenance in ovarian cells. Consistent with Khavinson bioregulation paradigm of chromatin remodeling and gene reactivation. Published data limited to Khavinson group.
Effects
REPRODUCTIVE (Female): Primary target system. Ovarian aging is one of the most dramatic biological clocks in the human body — women are born with ~1-2 million oocytes, declining to ~300,000 at puberty, ~25,000 by age 37, and near zero at menopause (~age 51). Ovarian reserve (AMH, antral follicle count) declines progressively. Zhenoluten targets ovarian tissue: (1) Granulosa cells — the support cells surrounding each oocyte; produce estradiol via aromatase (CYP19A1), express FSH receptors, produce AMH (anti-Müllerian hormone) and inhibin; (2) Theca cells — produce androgens (androstenedione) as substrate for estrogen; express LH receptors; (3) Ovarian stroma — structural support and blood supply. Proposed effects: normalization of steroidogenic enzyme expression for balanced estrogen/progesterone production; support for follicle development via growth factors GDF-9 and BMP-15 (essential for oocyte-granulosa communication); potential modulation of ovarian oxidative stress (a major driver of oocyte quality decline). ENDOCRINE: Ovarian hormones regulate the entire female endocrine system — estrogen affects bone, brain, cardiovascular, and skin health. Progesterone is essential for pregnancy maintenance and has neurological effects (calming, sleep-promoting). DHEA is also produced by ovarian stroma. MUSCULOSKELETAL: Estrogen is critical for bone density in women — menopause accelerates bone loss. Maintaining ovarian function preserves bone health. NEUROLOGICAL: Estrogen is neuroprotective — has BDNF-upregulating and anti-inflammatory effects in the brain. Progesterone is a neurosteroid. Menopause is associated with cognitive changes. CARDIOVASCULAR: Premenopausal women have lower cardiovascular risk than men — largely attributed to estrogen's beneficial effects on lipid profile and vascular function. Tier 3: Users report improved menstrual regularity, reduced menopausal symptoms (hot flashes, mood changes), and improved hormone panel results (estradiol, progesterone, AMH). Popular among women in perimenopause or those seeking to preserve fertility.
Practitioner Guide
DOSING TIPS: Standard protocol: 1-2 capsules daily for 10-30 days, repeated every 3-6 months. For perimenopausal support: 2 capsules daily for 30 days, timed to the follicular phase (days 1-14) of menstrual cycle if still cycling. Take with meals. SUPPLEMENT SYNERGIES: DHEA (10-25mg/day) — evidence supports ovarian reserve improvement (DHEA supplementation before IVF improves outcomes in poor responders). CoQ10 ubiquinol (200-600mg/day) — supports oocyte mitochondrial function; declining CoQ10 is implicated in age-related oocyte quality decline (Ben-Meir et al., Aging Cell, 2015). Myo-inositol (2-4g/day) — improves oocyte quality and FSH sensitivity in PCOS and age-related fertility decline. Vitamin D (2000-5000 IU/day) — VDR expressed in ovarian tissue; deficiency associated with poor AMH. Folate (methylfolate 800mcg+/day) — supports healthy ovarian folliculogenesis. Evening primrose oil (1000-3000mg/day) — GLA supports reproductive hormone balance. CYCLING: Standard Khavinson protocol. Can be aligned with menstrual cycle for women still cycling. CONTRAINDICATION NUANCES: Estrogen receptor-positive breast cancer — do not stimulate estrogen production. PCOS — may not be appropriate if hyperandrogenism is present. Endometriosis — estrogen promotion could theoretically worsen. Patients on hormonal contraceptives — ovarian function is suppressed by design; bioregulator may be counterproductive. Post-menopause with stable HRT — may complement or may be redundant; discuss with provider. STORAGE: Room temperature. PATIENT EDUCATION: This bioregulator targets the ovaries — the organs that produce eggs, estrogen, and progesterone. It aims to keep these organs functioning at their biological best for as long as possible. It is NOT hormone replacement — it supports your own hormone production. Best used in combination with CoQ10 (for egg quality), DHEA (for ovarian reserve), and a nutrient-rich diet. Track results with AMH, FSH, estradiol, and progesterone on day 3 and day 21 of your cycle.
Research Summary
TIER 1 (Gold Standard): No Western clinical trials specific to Zhenoluten. TIER 2 (Strong): Khavinson bioregulation theory. Ovarian aging and reproductive decline well-characterized (ASRM/ESHRE guidelines). DHEA for ovarian reserve improvement — multiple RCTs (Barad & Gleicher). CoQ10 for oocyte quality — Ben-Meir et al. (Aging Cell). TIER 3 (Moderate): Khavinson group publications on reproductive bioregulators. Practitioner reports. KEY FINDINGS: (1) Ovarian aging is a high-impact target with clear clinical significance. (2) Supporting interventions (DHEA, CoQ10) have Western evidence. (3) No independent validation of Zhenoluten specifically. GAPS: Standard Khavinson gaps. Ovarian reserve is particularly difficult to improve once depleted.